U.S. Markets open in 3 hrs 51 mins
  • S&P Futures

    3,340.50
    -42.50 (-1.26%)
     
  • Dow Futures

    26,932.00
    -433.00 (-1.58%)
     
  • Nasdaq Futures

    11,476.00
    -112.00 (-0.97%)
     
  • Russell 2000 Futures

    1,560.20
    -28.80 (-1.81%)
     
  • Crude Oil

    38.06
    -1.51 (-3.82%)
     
  • Gold

    1,902.70
    -9.20 (-0.48%)
     
  • Silver

    24.39
    -0.18 (-0.75%)
     
  • EUR/USD

    1.1755
    -0.0035 (-0.2939%)
     
  • 10-Yr Bond

    0.7780
    0.0000 (0.00%)
     
  • Vix

    35.93
    +3.47 (+10.69%)
     
  • GBP/USD

    1.2976
    -0.0065 (-0.5009%)
     
  • USD/JPY

    104.2650
    -0.2290 (-0.2192%)
     
  • BTC-USD

    13,655.44
    -54.58 (-0.40%)
     
  • CMC Crypto 200

    269.08
    +7.79 (+2.98%)
     
  • FTSE 100

    5,631.22
    -97.77 (-1.71%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Why Zimmer Biomet's Stock Is Trading Higher Today

Tanzeel Akhtar
·1 min read

Zimmer Biomet Holdings Inc (NASDAQ: ZBH) shares are trading higher on Wednesday after SVB Leerink maintained a Buy rating on the stock and raised its price target from $136 to $146.

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe and Japan.

Roughly 60% of total revenue is derived from sales of large joints, another 22% comes from extremities and trauma; the remaining portion is primarily related to spine and dental products.

Zimmer Biomet shares were trading up 5.50% at $131 during the time of publication on Wednesday. The stock has a 52-week high of $161.11 and a 52-week low of $74.37.

Latest Ratings for ZBH

Date

Firm

Action

From

To

Jul 2020

SVB Leerink

Maintains

Outperform

May 2020

JMP Securities

Maintains

Market Outperform

May 2020

UBS

Maintains

Buy

View More Analyst Ratings for ZBH
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.